Intercept Pharmaceuticals, Inc. Logo

Press releases

Date Title and Summary View
Toggle Summary Intercept Announces New Ocaliva® (obeticholic acid) and INT-767 Data to be Presented at EASL 2017
NEW YORK, April 19, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that multiple obeticholic acid,
View HTML
Toggle Summary Intercept to Present at Upcoming Conference
NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the
View HTML
Toggle Summary Intercept to Present at Upcoming Conference
NEW YORK, March 16, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the
View HTML
Toggle Summary NICE Recommends Ocaliva® (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis in England, Wales and Northern Ireland
First new medication for primary biliary cholangitis in nearly 20 years Rapid NICE approval only two months after marketing authorization in the EU; one of the fastest approvals to date for an orphan medicine NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc.
View HTML
Toggle Summary Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Business Update
Net Ocaliva ® (obeticholic acid or OCA) 4Q16 sales of $13.4 million, full year 2016 net sales of $18.2 million Enrollment of Phase 3 REGENERATE interim analysis cohort anticipated complet ion by mid-2017 Data expected from two Phase 2 trials for OCA in 2017 Planned initiation of Phase 2 trial of
View HTML
Toggle Summary Intercept to Report 2016 Full Year Financial Results on February 23 and Present at Upcoming Conferences
NEW YORK, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its fourth quarter and
View HTML
Toggle Summary Intercept to Provide Update on Phase 3 REGENERATE Trial of Obeticholic Acid for the Treatment of NASH Patients with Liver Fibrosis
Company to host investor conference call today at 8:30 a.m. ET
View HTML
Toggle Summary Intercept to Present at Upcoming Investor Conference
NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the
View HTML
Toggle Summary European Commission Grants Intercept's Ocaliva® (obeticholic acid) Marketing Authorization for the Treatment of Primary Biliary Cholangitis
NEW YORK, Dec. 14, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the European Commission has
View HTML
Toggle Summary Intercept to Present at Upcoming Investor Conference
NEW YORK, Dec. 09, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in following
View HTML